奥本海默控股维持Tarsus Pharmaceuticals(TARS.US)买入评级,维持目标价65美元 奥本海默控股分析师Francois Brisebois维持$Tarsus Pharmaceuticals(TARS.US)$买入评级,维持目标价65美元。根据TipRanks数据显示,该分析师近一年总胜率为35.1%,总平均回报率为-3.1%。提示: TipRanks为独立第三方,提供金融分析师的分析数据,并计算...
Tarsus Pharmaceuticals | 10-Q:2024财年三季报 11/14 05:18 Tarsus Pharmaceuticals | 8-K:Tarsus报告了2024年第三季度和年初至今的财务业绩和最近的业务成就 11/14 05:12 Tarsus Pharmaceuticals | SC 13G/A:超过5%持股股东披露文件(修正)-The Vanguard Group(5.51%) 11/13 07:08 Tarsus Pharmaceuticals | ...
© 2024 Tarsus Pharmaceuticals, Inc. All rights reserved. Tarsus, XDEMVY, and the associated logos are trademarks of Tarsus Pharmaceuticals, Inc.US--2400289 10/24
Find the latest Tarsus Pharmaceuticals, Inc. Common Stock (TARS) annual income statements, balance sheets, financial statements, ratios, and cash flow data at Nasdaq.com.
Bull or Bear, Seeking Alpha is there Markets change, but our community always has the latest news, in-depth analysis, and powerful stock ratings. Create Free Account TARSTarsus Pharmaceuticals, Inc. Options Chain & Prices 1.94K followers ...
Discover real-time Tarsus Pharmaceuticals, Inc. Common Stock (TARS) stock prices, quotes, historical data, news, and Insights for informed trading and investment decisions. Stay ahead with Nasdaq.
View Tarsus Pharmaceuticals, Inc. (TARS) capital structure, market cap, total debt, and overall enterprise value. TARS capital structure breakdown.
2023年7月,Tarsus Pharmaceuticals开发的XDEMVY(lotilaner滴眼液0.25%,中文名洛替拉纳)获得美国FDA批准用于治疗蠕形螨睑缘炎。据悉,该药物是美国FDA批准的首个也是目前唯一一个直接针对蠕形螨的治疗方法,蠕形螨是蠕形螨睑缘炎的根本原因。 睑缘炎是一种常见的慢性眼部睑缘疾病,可导致或加重眼表疾病,典型体征和症状包...
Tarsus Pharmaceuticals Inc. (TARS) $55.670.52(0.94%) Bid: 56.00 x 500Ask: 60.00 x 1700 January 3, 2025 4:00 PMESTVolume: 584,940 After Hours: $56.000.33(0.59%)January 3, 2025 6:56 PMESTVolume: 7,331 USDNasdaq Global SelectDelayed PriceMarket Closed Earnings High Target Price 84.00 ...
Tarsus Pharmaceuticals, Inc. and LianBio recently announced a strategic partnership to develop and commercialize TP-03 in Greater China (mainland China, Hong Kong, Taiwan, and Macau). TP-03 is a first-in-class investigational therapeutic in development for the treatment of Demodex blepharitis and ...